Cover Image
Market Research Report
Product code 
928277

Familial Chylomicronemia Syndrome (FCS) - Epidemiology Forecast to 2030

Published: Pre-Order | DelveInsight Business Research LLP | 100 Pages | Delivery time: 2-10 business days

Price

Back to Top
Familial Chylomicronemia Syndrome (FCS) - Epidemiology Forecast to 2030
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 100 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

Overview

DelveInsight's 'Familial Chylomicronemia Syndrome (FCS)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted FCS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Familial Chylomicronemia Syndrome (FCS) Understanding

Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder that is associated with the buildup of chylomicrons (a large lipoprotein particle that transports dietary fat and cholesterol in the body). It is also known as lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, endogenous hypertriglyceridemia, familial fat-induced hypertriglyceridemia, familial hyperchylomicronemia, and familial LPL deficiency, hyperlipidemia Type I (fredrickson), hyperlipoproteinemia Type IA, lipase D deficiency, and Burger-Grutz syndrome

The normal triglyceride levels are <150 mg/dL (or 1.7 mmol/L), but as the patients with FSC are incapable of breaking down chylomicrons (CM) that are rich in triglycerides, the levels can be as high as 10-20 times the normal threshold. FCS patients are at risk of severe recurrent abdominal pain and potentially fatal pancreatitis, long-term complications from pancreatic damage, and symptoms that can interfere with daily living. The leading cause behind the increase in the CM is the reduction or absence of LPL, which is an enzyme that helps to break down CM in the body. The patients with FCS encounter several severe symptoms before it is diagnosed.

The sign and symptoms that patients may experience include xanthomas (fatty deposits in the skin, usually on buttocks, knees, and arms), hepatosplenomegaly (swelling of liver and spleen), lipemia retinalis (milky appearance of retinal veins and arteries), and neurological symptoms such as depression and memory loss.

The clinical progression of FCS is unclear, in some cases, the patient may develop symptoms, including abdominal pain, quiet early in life, but may not be diagnosed until they are in their teens or 20s when the pancreatitis attacks become more frequent. Due to disease rarity and lack of understanding, FCS is often misdiagnosed or undiagnosed; however, the most number of patients have their diagnosis confirmed by a genetic test. Recently FCS score is developed to combat with misdiagnosis of FCS with multifactorial chylomicronemia syndrome (MCS).

Epidemiology Perspective by DelveInsight

The FCS epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The FCS epidemiology data are studied through FCS possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted Familial Chylomicronemia Syndrome epidemiology [segmented as Total Prevalence of FCS, Total Diagnosed Prevalence of FCS, Age-specific Diagnosed Prevalence of FCS, Severity- Specific Diagnosed Prevalence of FCS, and Treated Patient Pool of FCS] scenario of Familial Chylomicronemia Syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.

Familial Chylomicronemia Syndrome Detailed Epidemiology Segmentation

The total prevalent cases of FCS in the 7MM were found to be 5,801 in 2017 which is expected grow during the study period, i.e., 2017-2030.

Estimates show the highest prevalent population of FCS is in the United States followed by Japan, Germany, France, and the United Kingdom in 2017.

The total diagnosed prevalent population of FCS in the 7MM was assessed to be 2,900 in 2017 which is expected to increase during the study period.

FCS has been observed across all ages and this makes age as one of the major factors for this condition. During the understanding of this indication and analyses of the various research paper, we have observed that FCS cases are most commonly diagnosed in younger population (infants and younger adults). In 2017, higher number of cases estimated for the age group 0-10 years. Estimated number of cases in other age-groups were comparatively low.

About 70% of the total diagnosed prevalent cases were interfered significantly with their self-worth, emotional well-being, sleep, and mental functioning.

Scope of the Report

  • The FCS report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The FCS Report and Model provide an overview of the risk factors and global trends of FCS in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of FCS in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of FCS.
  • The report provides the segmentation of the FCS epidemiology by Diagnosed Prevalent Cases of FCS in the 7MM.
  • The report provides the segmentation of the FCS epidemiology by Age-specific Diagnosed Prevalent Cases of FCS in the 7MM.
  • The report provides the segmentation of the FCS epidemiology by Severity- Specific Diagnosed Prevalent of FCS in the 7MM.
  • The report provides the segmentation of the FCS epidemiology by Treated Patient Pool of FCS in the 7MM.

Report Highlights

  • 11-Year Forecast of Familial Chylomicronemia Syndrome epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Familial Chylomicronemia Syndrome
  • Prevalent Cases according to segmentation: Age-specific, Severity-specific
  • Treated cases of Familial Chylomicronemia Syndrome

KOL-Views

We interview, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over FCS scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Chylomicronemia Syndrome?
  • What are the key findings pertaining to the Familial Chylomicronemia Syndrome epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of Familial Chylomicronemia Syndrome across the 7MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Familial Chylomicronemia Syndrome?
  • Percentage of Familial Chylomicronemia Syndrome patients who are significantly affected in terms of their self-worth, emotional well-being, sleep, and mental functioning?

Reasons to buy

The Familial Chylomicronemia Syndrome Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Familial Chylomicronemia Syndrome market
  • Quantify patient populations in the global Familial Chylomicronemia Syndrome market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Familial Chylomicronemia Syndrome therapeutics in each of the markets covered
  • Understand the magnitude of Familial Chylomicronemia Syndrome population by its severity
  • The Familial Chylomicronemia Syndrome epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Familial Chylomicronemia Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Total Prevalent cases of FCS in the 7MM was assessed to be 5,801 in 2017, and are expected to increase during the study period. Among the European 5 countries, Germany had highest prevalent population of FCS, followed by France, United Kingdom and Italy. On the other hand, Spain had the lowest prevalent cases of FCS in 2017. Furthermore, Japan accounts for the 22% of the 7MM total prevalent patient population of FCS.

Table of Contents
Product Code: DIEI0879

Table of Contents

1. Key Insights

2. Executive Summary of FCS

3. Familial Chylomicronemia Syndrome (FCS): Disease Background and Overview

  • 3.1. Introduction
    • 3.1.1. Signs and Symptoms of FCS
    • 3.1.2. Genetics and Pathogenesis of FCS
  • 3.2. Diagnosis of FCS
    • 3.2.1. Diagnostic Algorithm

4. Epidemiology and Patient Population

  • 4.1. Key Findings: 7MM
  • 4.2. Assumptions and Rationale: 7MM
  • 4.3. Total Prevalence of FCS in the 7MM
  • 4.4. Total Diagnosed Prevalence of FCS in the 7MM
  • 4.5. Age-specific Diagnosed Prevalence of FCS in the 7MM

5. United States

  • 5.1. Total Prevalent cases of FCS in the United States
  • 5.2. Total Diagnosed Prevalent cases of FCS in the United States
  • 5.3. Severity- Specific Diagnosed Prevalence of FCS in the United States
  • 5.4. Treated Patient Pool of FCS in the United States

6. EU-5 Country-wise Epidemiology

  • 6.1. Germany
    • 6.1.1. Total Prevalent cases of FCS in Germany
    • 6.1.2. Total Diagnosed Prevalent cases of FCS in Germany
    • 6.1.3. Severity- Specific Diagnosed Prevalence of FCS in Germany
    • 6.1.4. Treated Patient Pool of FCS in Germany
  • 6.2. France
    • 6.2.1. Total Prevalent cases of FCS in France
    • 6.2.2. Total Diagnosed Prevalent cases of FCS in France
    • 6.2.3. Severity- Specific Diagnosed Prevalence of FCS in France
    • 6.2.4. Treated Patient Pool of FCS in France
  • 6.3. Italy
    • 6.3.1. Total Prevalent cases of FCS in Italy
    • 6.3.2. Total Diagnosed Prevalent cases of FCS in Italy
    • 6.3.3. Severity-Specific Prevalence of FCS in Italy
    • 6.3.4. Treated Patient Pool of FCS in Italy
  • 6.4. Spain
    • 6.4.1. Total Prevalent cases of FCS in Spain
    • 6.4.2. Total Diagnosed Prevalent cases of FCS in Spain
    • 6.4.3. Severity- Specific Diagnosed Prevalence of FCS in Spain
    • 6.4.4. Treated Patient Pool of FCS in Spain
  • 6.5. United Kingdom
    • 6.5.1. Total Prevalent cases of FCS in the United Kingdom
    • 6.5.2. Total Diagnosed Prevalent cases of FCS in the United Kingdom
    • 6.5.3. Severity- Specific Diagnosed Prevalence of FCS in the United Kingdom
    • 6.5.4. Treated Patient Pool of FCS in the United Kingdom

7. Japan

  • 7.1. Total Prevalent cases of FCS in Japan
  • 7.2. Total Diagnosed Prevalent cases of FCS in Japan
  • 7.3. Severity- Specific Diagnosed Prevalence of FCS in Japan
  • 7.4. Treated Patient Pool of FCS in Japan

8. Current Treatment Practices for FCS

  • 8.1. Novel Therapies
  • 8.2. Guidelines for FCS
  • 8.3. Dietary Guidelines for all Patients with FCS
  • 8.4. Dietary Guidelines by Population

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. Disclaimer

11. DelveInsight Capabilities

12. About DelveInsight

List of Tables

  • Table 1 Summary of FCS Epidemiology, and Key Events (2017-2030)
  • Table 2 Known Mutations Responsible for FCS
  • Table 3 Lipid Panel Parameters for Diagnosing FCS
  • Table 4 Major Sources Used
  • Table 5 Total prevalence of FCS in the 7MM (2017-2030)
  • Table 6 Total Diagnosed Prevalence of FCS in the 7MM (2017-2030)
  • Table 7 Age-specific Diagnosed Prevalence of FCS in the 7MM (2017-2030)
  • Table 8 Total Prevalent cases of FCS in the United States (2017-2030)
  • Table 9 Total Prevalent Cases of FCS in the United States (2017-2030)
  • Table 10 Severity- Specific Diagnosed Prevalence of FCS in the United States (2017-2030)
  • Table 11 Treated Patient Pool of FCS in the United States (2017-2030)
  • Table 12 Total Prevalent cases of FCS in Germany (2017-2030)
  • Table 13 Total Diagnosed Prevalent Cases of FCS in Germany (2017-2030)
  • Table 14 Severity- Specific Diagnosed Prevalence of FCS in Germany (2017-2030)
  • Table 15 Treated Patient Pool of FCS in Germany (2017-2030)
  • Table 16 Total Prevalent cases of FCS in France (2017-2030)
  • Table 17 Total Diagnosed Prevalent Cases of FCS in France (2017-2030)
  • Table 18 Severity- Specific Diagnosed Prevalence of FCS in France (2017-2030)
  • Table 19 Treated Patient Pool of FCS in France (2017-2030)
  • Table 20 Total Prevalent cases of FCS in Italy (2017-2030)
  • Table 21 Total Diagnosed Prevalent Cases of FCS in Italy (2017-2030)
  • Table 22 Severity-Specific Diagnosed Prevalence of FCS in Italy (2017-2030)
  • Table 23 Treated Patient Pool of FCS in Italy (2017-2030)
  • Table 24 Total Prevalent cases of FCS in Spain (2017-2030)
  • Table 25 Total Diagnosed Prevalent Cases of FCS in Spain (2017-2030)
  • Table 26 Severity-Specific Diagnosed Prevalence of FCS in Spain (2017-2030)
  • Table 27 Treated Patient Pool of FCS in Spain (2017-2030)
  • Table 28 Total Prevalent cases of FCS in the United Kingdom (2017-2030)
  • Table 29 Total Diagnosed Prevalent Cases of FCS in the United Kingdom (2017-2030)
  • Table 30 Severity-Specific Prevalence of FCS in the United Kingdom (2017-2030)
  • Table 31 Treated Patient Pool of FCS in the United Kingdom (2017-2030)
  • Table 32 Total Prevalent cases of FCS in Japan (2017-2030)
  • Table 33 Total Diagnosed Prevalent Cases of FCS in Japan (2017-2030)
  • Table 34 Severity- Specific Diagnosed Prevalence of FCS in Japan (2017-2030)
  • Table 35 Treated Patient Pool of FCS in Japan (2017-2030)
  • Table 36 Dietary and Treatment Guidelines for People with FCS throughout the Life Span

List of Figures

  • Figure 1 FCS SWOT Analysis
  • Figure 2 Signs and Symptoms of FCS
  • Figure 3 FCS Pathophysiology
  • Figure 4 Stepwise Approach to Identifying the Etiology of Severe Hypertriglyceridemia
  • Figure 5 A Practical Diagnostic Scoring System for FCS
  • Figure 6 Diagnostic Algorithm of FCS
  • Figure 7 Global Heat Map
  • Figure 8 Total prevalence of FCS in the 7MM (2017-2030)
  • Figure 9 Total Diagnosed Prevalence of FCS in the 7MM (2017-2030)
  • Figure 10 Age-specific Diagnosed Prevalence of FCS in the 7MM (2017-2030)
  • Figure 11 Total Prevalent cases of FCS in the United States (2017-2030)
  • Figure 12 Total Diagnosed Prevalent Cases of FCS in the United States (2017-2030)
  • Figure 13 Severity- Specific Diagnosed Prevalence of FCS in the United States (2017-2030)
  • Figure 14 Treated Patient Pool of FCS in the United States (2017-2030)
  • Figure 15 Total Prevalent cases of FCS in Germany (2017-2030)
  • Figure 16 Total Diagnosed Prevalent Cases of FCS in Germany (2017-2030)
  • Figure 17 Severity- Specific Diagnosed Prevalence of FCS in Germany (2017-2030)
  • Figure 18 Treated Patient Pool of FCS in Germany (2017-2030)
  • Figure 19 Total Prevalent cases of FCS in France (2017-2030)
  • Figure 20 Total Diagnosed Prevalent Cases of FCS in France (2017-2030)
  • Figure 21 Severity-Specific Prevalence of FCS in France (2017-2030)
  • Figure 22 Treated Patient Pool of FCS in France (2017-2030)
  • Figure 23 Total Prevalent cases of FCS in Italy (2017-2030)
  • Figure 24 Total Diagnosed Prevalent Cases of FCS in Italy (2017-2030)
  • Figure 25 Severity- Specific Diagnosed Prevalence of FCS in Italy (2017-2030)
  • Figure 26 Treated Patient Pool of FCS in Italy (2017-2030)
  • Figure 27 Total Prevalent cases of FCS in Spain (2017-2030)
  • Figure 28 Total Diagnosed Prevalent Cases of FCS in Spain (2017-2030)
  • Figure 29 Severity- Specific Diagnosed Prevalence of FCS in Spain (2017-2030)
  • Figure 30 Treated Patient Pool of FCS in Spain (2017-2030)
  • Figure 31 Total Prevalent cases of FCS in the United Kingdom (2017-2030)
  • Figure 32 Total Diagnosed Prevalent Cases of FCS in the United Kingdom (2017-2030)
  • Figure 33 Severity- Specific Diagnosed Prevalence of FCS in the United Kingdom (2017-2030)
  • Figure 34 Treated Patient Pool of FCS in in the United Kingdom (2017-2030)
  • Figure 35 Total Prevalent cases of FCS in Japan (2017-2030)
  • Figure 36 Total Diagnosed Prevalent Cases of FCS in Japan (2017-2030)
  • Figure 37 Severity- Specific Diagnosed Prevalence of FCS in Japan (2017-2030)
  • Figure 38 Treated Patient Pool of FCS in Japan (2017-2030)